SAN CARLOS, Calif.--(BW HealthWire)--Feb. 19, 2002--Neugenesis Corporation announced the grant of a European Patent Application for its proprietary method of producing recombinant monoclonal antibodies. This technology offers a significant alternative to the approach described in US Patent 6,331,415 issued to Genentech (NYSE:DNA - news) on December 18, 2001. This grant to Neugenesis extends the coverage of its US Patent 5,643,745 ``Heterologous Dimeric Proteins Produced In Heterokaryons'' and further expands the Neugenesis proprietary position for expression of all types of multimeric recombinant proteins including monoclonal antibodies.
``This new European coverage enhances our position in the field of monoclonal antibody expression,'' said Neugenesis president and CEO, W. Dorsey Stuart, Ph.D., author of the patents. ``We have nationalized the patent coverage to 18 member counties covered by the European Patent and we are very excited to have a technology which will be competitive with one of the founding companies of our industry,'' Stuart said.
Neugenesis Corporation is a privately held biotechnology company focused on leveraging fundamental research employing the filamentous fungus, Neurospora crassa, into commercial biotechnology applications.
This strategy has generated simple, inexpensive, rapid and proprietary methods that can produce monoclonal antibodies (MAbs); generate and rapidly identify new, unique gene sequences encoding commercially valuable products and; create combinatorial cellular arrays for rapid identification of commercially useful multi-component gene and protein variants.
For further information, please contact Dr. W. Dorsey Stuart at 650/508-9671 or info@neugenesis.com.
see also -
Message 15869597
Message 16087027 |
